Ireland-based medical technology firm Medtronic has introduced IN.PACT Admiral drug-coated balloon (DCB) in the US.
The IN.PACT Admiral DCB has been developed to treat patients with peripheral arterial disease (PAD) in the upper leg, a cardiovascular condition that results in leg pain and increases the risk of heart attack and stroke.
According to Medtronic, the DCB will reopen arteries located in the upper leg, specifically the superficial femoral and popliteal arteries, when they have been narrowed or blocked by plaque.
The US Food and Drug Administration (FDA) recently approved IN.PACT Admiral DCB, and it has been first used at NewYork-Presbyterian Hospital/Columbia University Medical Center by William Gray and Detroit Medical Center’s Harper Hospital in Michigan by Mahir Elder, and others.
Dr Gray said: "As an investigator in the clinical trial that contributed to this device’s FDA approval, I have seen firsthand how well the IN.PACT Admiral drug-coated balloon works as a treatment for peripheral arterial disease in the upper leg."
Medtronic noted that the US launch of IN.PACT Admiral DCB begins about a week after it completed the acquisition of Covidien, noted Medtronic
The IN.PACT Admiral DCB obtained CE mark approval in 2009.